RhoVac reports positive written response from the FDA regarding recently completed pre-IND meeting
RhoVac AB ("RhoVac") reports today, on April 26, 2019, that the company has received a written response from the Food and Drug Administration (FDA), USA regarding to the recently completed pre-IND meeting on development of the company’s drug candidate RV001. The subject of the meeting was to obtain agreement with the Agency regarding the scope of currently available data and the necessary data to support an IND submission for the clinical phase 2 trial in prostate cancer patients. Furthermore, the purpose of the meeting was to discuss with the agency and reach concurrence regarding the